These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 18186553)

  • 21. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
    Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
    Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
    Mikolasevic I; Filipec-Kanizaj T; Mijic M; Jakopcic I; Milic S; Hrstic I; Sobocan N; Stimac D; Burra P
    World J Gastroenterol; 2018 Apr; 24(14):1491-1506. PubMed ID: 29662288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    Larter CZ; Chitturi S; Heydet D; Farrell GC
    J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.
    Lim JS; Mietus-Snyder M; Valente A; Schwarz JM; Lustig RH
    Nat Rev Gastroenterol Hepatol; 2010 May; 7(5):251-64. PubMed ID: 20368739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
    Schuppan D; Schattenberg JM
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease: Evolving paradigms.
    Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
    World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.
    Milić S; Stimac D
    Dig Dis; 2012; 30(2):158-62. PubMed ID: 22722431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease.
    Pacifico L; Di Martino M; De Merulis A; Bezzi M; Osborn JF; Catalano C; Chiesa C
    Hepatology; 2014 Feb; 59(2):461-70. PubMed ID: 23843206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology of non-alcoholic fatty liver disease.
    Bellentani S; Scaglioni F; Marino M; Bedogni G
    Dig Dis; 2010; 28(1):155-61. PubMed ID: 20460905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
    Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
    Williams CD; Stengel J; Asike MI; Torres DM; Shaw J; Contreras M; Landt CL; Harrison SA
    Gastroenterology; 2011 Jan; 140(1):124-31. PubMed ID: 20858492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
    Boppidi H; Daram SR
    Postgrad Med; 2008 Jul; 120(2):E01-7. PubMed ID: 18654060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
    Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies.
    Fan JG; Peng YD
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):572-8. PubMed ID: 18086620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
    Simon TG; Corey KE; Chung RT; Giugliano R
    Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.